Palvella Therapeutics Inc (PVLA)

Apr 15, 2026

Palvella reports 2025 results, advances QTORIN drug pipeline - MSN

Apr 15, 2026

Apr 14, 2026

Palvella Appoints Kent Taylor as Senior Vice President of Sales - MyChesCo

Apr 14, 2026

Apr 13, 2026

Palvella Therapeutics, Inc. Files Form 8-K with SEC – Company Details, Address, and Key Information - Minichart

Apr 13, 2026

Apr 13, 2026

Palvella Therapeutics appoints John Doux to board of directors By Investing.com - Investing.com South Africa

Apr 13, 2026

Apr 13, 2026

Palvella Therapeutics appoints John Doux, M.D., to board of directors By Investing.com - Investing.com South Africa

Apr 13, 2026

Apr 13, 2026

Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors - Bitget

Apr 13, 2026

Apr 13, 2026

Palvella Therapeutics appoints John Doux, M.D., to board of directors - Investing.com

Apr 13, 2026

Apr 13, 2026

Palvella Therapeutics Adds Independent Dermatology Expert to Board - TipRanks

Apr 13, 2026

Apr 13, 2026

Palvella Therapeutics Appoints Dr. John D. Doux to Board of Directors to Advance Rare Disease Initiatives - Quiver Quantitative

Apr 13, 2026

Apr 13, 2026

Palvella Therapeutics appoints John Doux to board of directors - Investing.com

Apr 13, 2026

Apr 13, 2026

Form 8-KCurrent report - ADVFN

Apr 13, 2026

Apr 11, 2026

Palvella Therapeutics (PVLA) price target increased by 15.78% to 224.97 - MSN

Apr 11, 2026

Apr 10, 2026

Volatility Watch: How does Palvella Therapeutics Inc compare to its peersEarnings Growth Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn

Apr 10, 2026

Apr 08, 2026

Palvella appoints McDonough as SVP of market access, patient services - MSN

Apr 08, 2026

Apr 08, 2026

PVLA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 08, 2026

Apr 08, 2026

Palvella Therapeutics, Inc. (PVLA) stock price, news, quote and history - Yahoo Finance Singapore

Apr 08, 2026

Apr 08, 2026

Palvella Reports 2025 Results, Advances QTORIN Drug Pipeline - MyChesCo

Apr 08, 2026

Apr 07, 2026

Palvella Publishes Review on Lymphatic Malformations in Medical Journal - MyChesCo

Apr 07, 2026

Apr 07, 2026

Palvella Therapeutics Appoints Kent Taylor as Senior Vice President of Sales - citybiz

Apr 07, 2026

Apr 07, 2026

Palvella Showcases QTORIN Platform Momentum and Commercial Readiness - TipRanks

Apr 07, 2026

Apr 07, 2026

Palvella Therapeutics Appoints Kent Taylor as Senior Vice President of Sales to Drive QTORIN™ Launch for Rare Skin Disease - Quiver Quantitative

Apr 07, 2026

Apr 07, 2026

Palvella posts corporate presentation highlighting positive Phase 3 SELVA data and NDA plans - TradingView — Track All Markets

Apr 07, 2026

Apr 07, 2026

Palvella (NASDAQ: PVLA) shows pivotal rare-disease data and $274M cash runway - Stock Titan

Apr 07, 2026

Apr 07, 2026

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales - GlobeNewswire

Apr 07, 2026

Apr 06, 2026

European Patent Office grants Palvella patent for QTORIN rapamycin - MSN

Apr 06, 2026

Apr 06, 2026

HC Wainwright & Co. Maintains Palvella Therapeutics (PVLA) Buy Recommendation - MSN

Apr 06, 2026

Apr 05, 2026

Breakout Move: What makes Palvella Therapeutics Inc stock attractive today2026 Selloffs & Free Growth Oriented Trading Recommendations - baoquankhu1.vn

Apr 05, 2026

Apr 05, 2026

Palvella Appoints McDonough as SVP of Market Access, Patient Services - MyChesCo

Apr 05, 2026

Apr 05, 2026

Can Palvella Therapeutics Inc lead its sector in growthPortfolio Update Summary & Safe Entry Zone Identification - baoquankhu1.vn

Apr 05, 2026

Apr 04, 2026

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Apr 04, 2026

Apr 03, 2026

Rare disease breakthrough? Palvella reports strong phase 2 results - MSN

Apr 03, 2026

Apr 03, 2026

HC Wainwright Brokers Decrease Earnings Estimates for PVLA - MarketBeat

Apr 03, 2026

Apr 03, 2026

Lifesci Capital Brokers Decrease Earnings Estimates for PVLA - MarketBeat

Apr 03, 2026

Apr 02, 2026

What is HC Wainwright's Estimate for PVLA Q1 Earnings? - marketbeat.com

Apr 02, 2026

Apr 02, 2026

PVLA Stock Price, Quote & Chart | PALVELLA THERAPEUTICS INC (NASDAQ:PVLA) - ChartMill

Apr 02, 2026

Apr 01, 2026

Palvella’s Phase III Success And Fast Track Status Test Current Valuation - Yahoo Finance

Apr 01, 2026

Apr 01, 2026

Mizuho reiterates Palvella Therapeutics stock rating on pipeline By Investing.com - Investing.com Canada

Apr 01, 2026

Apr 01, 2026

Chardan Raises Price Target on Palvella Therapeutics to $240 From $210, Keeps Buy Rating - marketscreener.com

Apr 01, 2026

Apr 01, 2026

Oppenheimer raises Palvella Therapeutics price target on valuation By Investing.com - Investing.com India

Apr 01, 2026

Mar 31, 2026

US Stocks Recap: What makes Palvella Therapeutics Inc stock attractive todayEarnings Overview Summary & Daily Stock Trend Reports - baoquankhu1.vn

Mar 31, 2026

Mar 31, 2026

Palvella Hire Highlights QTORIN Launch Plans And Deep Rare Skin Focus - Sahm

Mar 31, 2026

Mar 31, 2026

Chardan raises Palvella stock price target to $240 on pipeline progress - Investing.com Canada

Mar 31, 2026

Mar 31, 2026

Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $240.00 - MarketBeat

Mar 31, 2026

Mar 31, 2026

Palvella Highlights 2025 Results and SELVA Phase 3 Progress - TipRanks

Mar 31, 2026

Mar 31, 2026

Stifel reiterates Buy rating on Palvella stock, $250 target By Investing.com - Investing.com Canada

Mar 31, 2026

Mar 31, 2026

Oppenheimer raises Palvella Therapeutics price target on valuation - investing.com

Mar 31, 2026